Experts warn of dramatic spikes in US households' energy bills this summer: 'Unprecedented'
A new AccuWeather report forecasts searing temperatures, more frequent droughts, and higher power bills across large swaths of the United States this summer.
According to the news release shared by PR Newswire, hotter weather is expected to impact millions of Americans, with meteorologists predicting temperatures three degrees or higher above average for much of the U.S. Higher energy bills are expected as people crank up the air conditioning to find relief.
"Make sure your air conditioners are ready for another hot summer across much of the country, especially the western and central U.S. We expect a summer with more extremes, including extreme heat waves, expanding drought and the potential for big wildfires and major hurricanes later in the summer," AccuWeather Lead Long-Range Expert Paul Pastelok said.
Droughts across the western U.S. could spark wildfires, even during monsoon season when thunderstorms trigger lightning strikes that hit dry landscape and potentially cause it to burn.
Overall temperatures are projected to climb above historical averages in 45 states, with 14 in the central and western U.S. expected to see the highest temperatures.
Heatwaves are extremely dangerous for the elderly, young, immunocompromised, or anyone without air conditioning, as extreme heat causes more deaths than hurricanes, floods, tornadoes, and cold weather combined, according to AccuWeather senior meteorologist and climate expert Brett Anderson.
The impacts of scorching summer temperatures are usually worse in major cities, where the urban heat island effect makes the surrounding air feel hotter than it would in rural or suburban areas because of the dark-colored asphalt and concrete buildings.
If someone lacks air conditioning, they're at a higher risk of experiencing heat-related illnesses and other health issues. In highly humid climates, warm weather can be even deadlier because the body struggles to maintain a safe core temperature without the ability to cool down through sweating.
Recent studies show an alarming increase in heat-related deaths over the past two decades across the U.S., and the trend is likely to continue as global temperatures continue to climb because of the shifting climate.
Human activities — namely the burning of dirty fuels such as oil and gas — are driving rapid changes in the climate that are contributing to more extreme weather. Scientists have been observing these long-term shifts in weather patterns since the mid-1800s, but the effects haven't been felt to an extreme degree until the past decade.
How often do you worry about your energy bills?
Every day
A few times a week
A few times a month
Only when I pay it
Click your choice to see results and speak your mind.
NASA reported that "the rate of change since the mid-20th century is unprecedented over millennia."
"While Earth's climate has changed throughout its history, the current warming is happening at a rate not seen in the past 10,000 years," it added.
Rising global temperatures act like "steroids for weather," as climate tech investor Molly Wood explained. Burning dirty fuels causes the atmosphere to trap excess heat and hold more moisture, which triggers more intense storms, hurricanes, wildfires, and every other kind of natural disaster.
Addressing the overheating planet is costly, but ignoring the consequences is far more expensive. Luckily, governments, climate tech companies, and other organizations have come up with solutions to help us withstand the effects of the warming world. For example, the U.S. government just unlocked $7 billion in solar panel incentives that will help homeowners switch to cleaner energy that can reduce the pollution in the atmosphere, thereby contributing to a cooler planet.
Companies have also made breakthroughs in battery tech that allow for longer storage, increasing grid resiliency and ensuring people have enough power at night when demand peaks.
Installing solar panels with a backup battery system can make your home safer and more prepared to handle extreme weather events during power outages. Plus, your energy costs will be drastically lower or even reduced to nothing, allowing you to save that money for other home improvements that increase security as the climate shifts.
If you're interested in going solar, the online marketplace EnergySage offers a free service that allows you to compare quotes from vetted installers and save up to $10,000 on solar installations.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Miami Herald
an hour ago
- Miami Herald
Fed Chair Powell has closed door meeting at the White House on interest rate cuts
Federal Reserve Bank Chair Jerome Powell stayed the course after being summoned to an economic woodshed at the White House by President Trump, who has been vocal about demands that the Fed ax interest rates. The May 29 faceoff was Powell's first visit to the White House during Trump's second tour. In a statement, Powell's office said the meeting's agenda was to "to discuss economic developments, including for growth, employment, and inflation." Don't miss the move: Subscribe to TheStreet's free daily newsletter Both sides said the meeting was at the invitation of the president, who told Powell in person what he's been saying and tweeting for months: the Fed's refusal to cut interest rates was a "mistake" damaging the economy. The Board of Governors of the Federal Reserve System voted unanimously in early May to approve the establishment of the primary credit rate at the existing level of 4.5% – which means interest rates for lenders, consumers and the rest of Americans won't be budging in the near term, much to the dismay of the Trump administration. This stance "will be updated as appropriate to reflect decisions of the Federal Open Market Committee or the Board of Governors regarding details of the Federal Reserve's operational tools and approach to implement monetary policy," the central bank said in a statement. XinhuaTrump's repeated demands underscore the volatility of U.S. trade policy and provide another flash point for global worries about fiscal policy, which have sent bond yields sharply higher. The whiplashed tariffs, primarily those against China and the E.U., add to economic jitters, Related: Fed official sends strong message about interest-rate cuts Since April 2, or "Liberation Day," tariff threats and trade jitters have spooked buyers and sellers into a seemingly endless roller-coaster ride. Many market, economic, and financial experts have begun publicly warning of a recession within a few months, while others predict a nation stuck in a nasty stagflation. The Federal Reserve has a dual mandate to target low inflation and unemployment. The central bank can raise interest rates to slow inflation, which can cause unemployment. Or it can cut rates to boost job growth, but that can cause inflation. Monetary and stock market experts expect the Fed will lower interest rates by one quarter point in September. Trump told Powell in their meeting he wanted the cuts sooner. Related: Jamie Dimon sends terse message on stocks, economy The Fed's statement following the White House meeting said Powell "did not discuss his expectations for monetary policy, except to stress that the path of policy will depend entirely on incoming economic information and what that means for the outlook." A White House spokeswoman agreed with the statement, but added that the president pressed for immediate action to lower the rates. Powell also said in the Fed statement that he and his colleagues will set monetary policy "as required by law, to support maximum employment and stable prices and will make those decisions based solely on careful, objective, and non-political analysis." Powell will give the opening remarks June 2 at the Federal Reserve Board's International Finance (IF) Division 75th Anniversary Conference, Washington, D.C. The conference will feature a series of panel discussions focused on the division's history and people, as well as an academic panel and presentations by former IF economists. Related: Veteran fund manager who predicted April rally updates S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
an hour ago
- Yahoo
Could you see the northern lights over RI, New England tonight? It's possible. See map
The northern lights may be visible over a large swath of New England tonight due to a large geomagnetic storm, possibly even dipping into northern Rhode Island. "The G4 (Severe) geomagnetic storm watch remains in effect for tonight, June 1st (EDT), as CME passage continues," the Space Weather Prediction Center said in a 2 p.m. alert on June 1. "There are indications that the coronal mass ejection (CME) passage is weakening, but the solar wind conditions remain elevated, therefore additional periods of G3-G4 (Strong-Severe) levels remain possible. However, we now anticipate that conditions should weaken enough by tomorrow evening, June 2nd (EDT), that G1 (Minor) storm levels is the most likely peak response." The National Oceanic and Atmospheric Administration's Space Weather Prediction Center prediction map is showing that all of New Hampshire, Maine and Vermont have a chance to see the spectacle tonight, including a large chunk of Massachusetts. The possible view line is just touching Rhode Island, meaning there's a chance that people will see them. The question is, will the weather cooperate? AccuWeather is currently forecasting partly cloudy skies, so if the lights reach it's possible cloud cover will be a problem. The sun is currently at solar maximum, according to NASA, the peak of activity in its natural cycle, which is creating more opportunities to see the northern lights. Here's what to know. According to the National Oceanic and Atmospheric Administration's (NOAA) aurora forecast, the northern lights may reach to Rhode Island tonight, but only in the northern tip of the state. However, odds improve if people make a trip to Massachusetts where much of the state is firmly in the view line, and become even better in northern New England and New York. The northern lights are typically most visible between 10 p.m. and 2 a.m. according to NOAA. "Best aurora is usually within an hour or two of midnight (between 10 PM and 2 AM local time)," the said. "These hours of active aurora expand towards evening and morning as the level of geomagnetic activity increases. There may be aurora in the evening and morning but it is usually not as active and therefore, not as visually appealing." As always, dark skies make for better stargazing. "We typically suggest getting away from cities and find a open field or hilltop to lay out under the stars and wait for the show to really peak at the late evening or early morning hours," Massachusetts Institute of Technology Technical Instructor and Observatory Manager Tim Brothers said in a past interview with Wicked Local. He continued, "In New England, heading for a local conservation area or park that keeps lighting off at night is ideal. Another option is a coastline away from the larger cities — the benefit being that the constellation where you will see most of the 'shooting stars.'" If you want a chance at seeing the Northern Lights, here are some websites you can monitor the sun's activity: The Space Weather Prediction Center Aurora forecast page (NOAA) Aurora Reach Aurora Alerts This article originally appeared on The Providence Journal: Severe geomagnetic storm could bring northern lights to RI. See map
Yahoo
an hour ago
- Yahoo
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)". Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics